Impact of Elexacaftor/Tezacaftor/Ivacaftor on Cystic Fibrosis Liver Tests in a Real-World Cohort with and Without Baseline CFLD

被引：0
|
作者：
Bowen, M. [1 ]
Sample, E. [1 ]
Collins, A. [1 ]
Singhal, A. [1 ]
Brown, A. [1 ]
机构：
[1] Inova Fairfax Hosp, Adv Lung Dis & Lung Transplant, Falls Church, VA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2028
引用
收藏
页数：1
相关论文
共 50 条
  • [31] THE USE OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS POST-LIVER TRANSPLANTATION
    Ragan, H. H.
    Autry, E.
    Bomersback, T.
    Hewlett, J.
    Kormelink, L.
    Safirstein, J.
    Shanley, L.
    Lubsch, L.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S349 - S350
  • [32] Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis
    Sheikh, Shahid
    Britt, Rodney D. Jr Jr
    Ryan-Wenger, Nancy A.
    Khan, Aiman Q.
    Lewis, Brandon W.
    Gushue, Courtney
    Ozuna, Hazel
    Jaganathan, Devi
    McCoy, Karen
    Kopp, Benjamin T.
    PEDIATRIC PULMONOLOGY, 2023, 58 (03) : 825 - 833
  • [33] Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6-11 years with cystic fibrosis in a real-world setting
    Dacco, Valeria
    Rosazza, Chiara
    Mariani, Alessandra
    Rizza, Carmela
    Ingianni, Nicolo
    Nazzari, Erica
    Terlizzi, Vito
    Blasi, Francesco Arturo
    Alicandro, Gianfranco
    PEDIATRIC PULMONOLOGY, 2024, 59 (11) : 2792 - 2799
  • [34] Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis
    Marshall, Landon Z.
    Espinosa, Rachel
    Starner, Catherine, I
    Gleason, Patrick P.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (06): : 599 - 606
  • [35] The Impact of Elexacaftor/ Tezacaftor/Ivacaftor on the Protease-Antiprotease Balance in Cystic Fibrosis Airways
    Casey, M.
    Gabillard-Lefort, C.
    Fraughen, D.
    Herron, M.
    Murphy, M. P.
    Kerr, O.
    Lyons, A.
    Marron, E.
    Gunaratnam, C.
    Reeves, E. P.
    McElvaney, N. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [36] THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19
    MILES, B.
    CHACKO, J.
    CHEST, 2022, 161 (06) : 294A - 294A
  • [37] A systematic review of the impact of Elexacaftor/Tezacaftor/Ivacaftor on body composition in people with cystic fibrosis
    Kinsey, Laura
    Winterbottom, Hannah
    Hudson, Lydia
    Lal, Simon
    Jones, Andrew M.
    Burden, Sorrel
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2025,
  • [38] Impact of Elexacaftor/Tezacaftor/Ivacaftor on airway inflammation and clinical outcomes in Patients with Cystic Fibrosis
    Casey, Michelle
    Gabillard-Lefort, Claudie
    Kerr, Orla
    Marron, Elaine
    Lyons, Anne-Marie
    Cullen, Lydia
    Murphy, Alexandra
    Gunaratnam, Cedric
    Reeves, Emer P.
    McElvaney, Noel G.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 5) : 179 - 179
  • [39] Impact of elexacaftor/tezacaftor/ ivacaftor on fat soluble vitamin levels in children with cystic fibrosis
    Ly, Selina
    Robinson, Paul
    Douglas, Tonia
    Mitchell, Penny
    RESPIROLOGY, 2024, 29 : 43 - 43
  • [40] Real World Adverse Effects of Elexacaftor/Tezacaftor/Ivacaftor in People With Cystic Fibrosis Ages 6-11 Years
    Pettit, Rebecca S.
    Ravikumar, Bharathi
    PEDIATRIC PULMONOLOGY, 2025, 60 (04)
12345